Will The Pfizer-Mylan Deal Face Antitrust Hurdles?
Executive Summary
It's possible the US Federal Trade Commission could require Mylan or Pfizer's Upjohn to divest some pharmaceuticals as the companies have more than 70 overlapping products.
You may also be interested in...
The End Is Nigh For Mylan, But How Different Will The New Company Be?
Mylan will be merged into a new company with Pfizer’s Upjohn, closing the chapter on a generic drug powerhouse that will be remembered as much for scandal as success.
Love From Shanghai: Upjohn Started Here But Will It Stay Post-Mylan?
Opened with a big splash just two months ago in a brand new headquarters in Shanghai, Pfizer's Upjohn established products subsidiary is now merging with Mylan to create the world's largest generics group, stirring up local concerns that the focus could shift from China back to the US.
When It Comes To FTC M&A Review, The Times May Be A Changin'
Spark signaled in an SEC filing that its merger with Roche could be delayed into 2020, fueling more speculation that FTC is increasing scrutiny over biopharma mergers.